Newsroom | 4490 results

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization on the primary endpoint of gait speed as assessed by the 10-Meter Walk Test (10...

BERLIN--(BUSINESS WIRE)--Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for PD. At the same time, first European participants have been randomized in REGENERATE-PD, a Phase II clinical trial of AB-1005, an investigational gene therapy. Both therapies are focused on treating moderate-stage PD and are...

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that is has achieved a key research milestone in one of its collaborative programs with Alexion, AstraZeneca Rare Disease....

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Stereotactic Neuro-Navigation System Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Asia-Pacific stereotactic neuro-navigation system market is projected to reach $702.2 million by 2035 from $170.7 million in 2024, growing at a CAGR of 14.05% during the forecast period 2025-2035. The market for APAC stereotactic neuro-navigation systems is expanding quickly due to the increased prevalence of ne...

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Robotic Neurosurgery Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Asia-Pacific robotic neurosurgery market is projected to reach $587.0 million in 2035 and estimated $92.6 million in 2025, growing at a CAGR of 20.28% during the forecast period 2025-2035 The increasing popularity of minimally invasive procedures is speeding up adoption even more because they lower surgical risks and recuperati...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 share...

TORONTO & SEATTLE--(BUSINESS WIRE)--Panaxium Research Signs Exclusive IP Agreement with University of Washington to Advance Dynamic Neurostimulation Stroke Recovery Therapy...

COPENHAGUE, Dinamarca--(BUSINESS WIRE)--Neumirna Therapeutics, una empresa biotecnológica que desarrolla terapias basadas en ARN para enfermedades neurológicas, ha anunciado hoy el nombramiento de Ellen K. Donnelly, doctora en Medicina , como directora ejecutiva. Ellen cuenta con más de 20 años de experiencia en puestos de responsabilidad en el ámbito de la neurociencia y las enfermedades raras, tanto en empresas farmacéuticas internacionales como en empresas biotecnológicas innovadoras. Se une...

KOPENHAGEN, Denemarken--(BUSINESS WIRE)--Neumirna Therapeutics, een biotechnologiebedrijf dat op RNA gebaseerde therapieën voor neurologische ziekten ontwikkelt, kondigde vandaag de benoeming aan van Ellen K. Donnelly, Ph.D. als Chief Executive Officer. Ellen heeft meer dan 20 jaar ervaring als leidinggevende op het gebied van neurowetenschappen en zeldzame ziekten bij zowel wereldwijde farmaceutische bedrijven als innovatieve biotechs. Ze komt bij Neumirna vanuit haar rol als CEO van Abliva AB...

COPENHAGUE, Danemark--(BUSINESS WIRE)--Neumirna Therapeutics, une société de biotechnologie spécialisée dans le développement de thérapies à base d’ARN pour les maladies neurologiques, a annoncé aujourd’hui la nomination d’Ellen K. Donnelly, Ph.D. au poste de directrice générale Mme Donnelly apporte plus de 20 ans d’expérience en neurosciences et maladies rares, acquise au sein de sociétés pharmaceutiques internationales et de sociétés de biotechnologie innovantes. Elle rejoint Neumirna après a...